Physician profile
Jueyang Wei
NPI 1346249455
$14,492.90
in general payments reported to CMS, 2019-2025
46 companies · $2,286 in 2025
The $2,286 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,509 · 2020: $1,503 · 2021: $1,555 · 2022: $1,970 · 2023: $2,390 · 2024: $2,279 · 2025: $2,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,800 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,800.34 |
| Education | $155.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,365.35 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $2,068.92 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Novartis Pharmaceuticals Corporation | $1,472.69 | 2019-2025 | |
| Eisai INC. | $1,410.94 | 2019-2025 | |
| Lilly USA, LLC | $599.26 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Celgene Corporation | $512.31 | 2021-2025 | Zeposia |
| Emd Serono, INC. | $493.99 | 2019-2025 | Mavenclad |
| Sk Life Science, INC. | $451.50 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $436.92 | 2019-2024 | Ultomiris |
| Pfizer INC. | $412.88 | 2023-2025 | |
| Genzyme Corporation | $341.41 | 2019-2022 | |
| Allergan, INC. | $311.03 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $254.80 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $240.83 | 2019-2021 | |
| Argenx US, INC. | $219.94 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jueyang Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.